Health Management & Information Science

Health Management & Information Science

Cost-effectiveness of radiotherapy during surgery compared with external radiation therapy in the treatment of women with breast cancer

Document Type : Articles

Authors
Hedie Mosalanezhad
Zahra Kavosi
Khosro Keshavarz
Majid Akrami
Maryam Sarikhani
Abstract
Introduction: Intraoperative radiation therapy device (IORT) is one of the several options for partial breast irradiation. IORT is sent to the tumor bed during surgery and can be replaced with conventional standard therapy (EBRT). The aim of this study was to evaluate the safety and effectiveness of IORT machine compared with EBRT and to determine the dominant option in terms of the cost-effectiveness.Method: This study was conducted in two phases; the first phase was a comprehensive review of the electronic databases search that was extracted after extraction and selection of the articles used in this article on effectiveness outcomes. Data collection form was completed by professionals and experts to estimate the cost of treatment, intraoperative radiotherapy and radiotherapy cost when using external radiation therapy process; direct costs were considered from the perspective of service provider and they were calculated in the second phase to determine the option of cost-effective ICER. Excel software was used for data analysis and sensitivity analysis was performed to determine the strength of the results of cost-effectiveness.Results:18 studies were selected but only 8 of them were shown to have acceptable quality. The consequences like “rate of cancer recurrence”, “seroma”, “necrosis”, “toxic”, “skin disorders and delayed wound healing” and “spread the pain” were among the consequences used in the selected articles. The total costs for each patient during a course of treatment for EBRT and IORT were estimated 1398 and $5337.5, respectively. During the analysis, cost-effectiveness of the consequences of cancer recurrence, seroma, necrosis and skin disorders and delayed wound healing ICER was calculated. And IORT was found to be the dominant supplier in all cases. Also, in terms of implications of toxicity and prevalence of pain, IORT had a lower cost and better effectiveness and consequently the result was more cost effective than EBRT.Conclusion: According to the results of this study, the difference between the two devices in terms of effectiveness was much lesser than that in terms of the cost of the two devices. According to the results of IORT machine, it is the dominant supplier compared with EBRT. From the cost-effectiveness perspective, Iran Ministry of Health can consider IORT system as an option for entering Iranian health system. But the ethical and cultural considerations in the use of the device must be taken into account.Keywords: Health technology assessment, IORT, EBRT, Cost-effective analysis, Systematic review
  1. Anderson WF, Jatoi I, Devesa SS. Assessing the impact of screening mammography: Breast cancer incidence and mortality rates in Connecticut (1943-2002). Breast Cancer Res Treat. 2006;99(3):333-40.
  2. Da vita V, Helman J, Rosenbery S. Cancer Principies 8 Practice Of Oncology. 6th ed.; 2001.
  3. Perez C, Bradg L. Principles and Practive of Radiation Oncology. 3rd ed.; 1998.
  4. Fazel A, Tirgari B, Mokhber N, Koushyar M, Esmaily H. The Effect of Mastectomy on Mood and Quality of Life in Breast Cancer Patients. SSU_Journals. 2008;16(3):317-.
  5. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005;104(6):1149-57.
  6. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355(9217):1822.
  7. Mancias JD, Taghian AG. Accelerated partial breast irradiation using TARGIT: the pros, cons and the need for long-term results. Expert Rev Anticancer Ther. 2010;10(12):1869-75.
  8. Vaidya JS, Baum M, Tobias JS, D’Souza DP, Naidu SV, Morgan S, et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol. 2001;12(8):1075-80.
  9. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-106.
  10. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine. 2002;347(16):1233-41.
  11. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase3 trial. The Lancet. 2010;376(9735):91-102.
  12. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol. 2008;53(13):R193-241.
  13. Arthur DW, Vicini FA. Accelerated partial breast irradiation as a part of breast conservation therapy. J Clin Oncol. 2005;23(8):1726-35.
  14. Wazer DE, Berle L, Graham R, Chung M, Rothschild J, Graves T, et al. Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):889-97.
  15. Pignol JP, Rakovitch E, Keller BM, Sankreacha R, Chartier C. Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. Int J Radiat Oncol Biol Phys. 2009;73(5):1482-8.
  16. Intra M, Gentilini O, Veronesi P, Ciocca M, Luini A, Lazzari R, et al. A new option for early breast cancer patients previously irradiated for Hodgkin’s disease: intraoperative radiotherapy with electrons (ELIOT). Breast Cancer Res. 2005;7(5):R828-32.
  17. Vicini FA, Remouchamps V, Wallace M, Sharpe M, Fayad J, Tyburski L, et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. International Journal of Radiation Oncology* Biology* Physics. 2003;57(5):1247-53.
  18. Wenz F, Welzel G, Blank E, Hermann B, Steil V, Sutterlin M, et al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys. 2010;77(5):1309-14.
  19. Garrido M, Gerhardus A, Rottingen J, Busse R. Developing Health Technology Assessment to address health care system needs. Health policy. 2010;49:196-202.
  20. NaserHamzeKhanloo M, Bazyar M. Role and Necessity of Health Technology Assessment (HTA) in Health System. Journal of Health. 2010;1(2):59-68.
  21. Ravaghi H, Sari AA, Sarvari S, Mobinizadeh MR. The Effectiveness of PET-Scan in Diagnosis and Treatment of Non-Small Cell Lung Carcinoma (NSCLC) and Lymphoma: A Comprehensive Review of Literature. Journal of Isfahan Medical School. 2012;29(167).
  22. Shahbazian H, Hadadzadeh M. The Impact of Intraluminal Vancomycin Adminstration on Prevention of Hemodialysis Catheter-Related Infections. Journal of Kerman University of Medical Sciences. 2007;14(3):211-5.
  23. Andersen KG, Gartner R, Kroman N, Flyger H, Kehlet H. Persistent pain after targeted intraoperative radiotherapy (TARGIT) or external breast radiotherapy for breast cancer: a randomized trial. Breast. 2012;21(1):46-9.
  24. Della Sala SW, Pellegrini M, Bernardi D, Franzoso F, Valentini M, Di Michele S, et al. Mammographic and ultrasonographic comparison between intraoperative radiotherapy (IORT) and conventional external radiotherapy (RT) in limited-stage breast cancer, conservatively treated. Eur J Radiol. 2006;59(2):222-30.
  25. Reitsamer R, Peintinger F, Kopp M, Menzel C, Kogelnik HD, Sedlmayer F. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. Strahlentherapie und Onkologie. 2004;180(1):38-44.
  26. Ruch M, Brade J, Schoeber C, Kraus-Tiefenbacher U, Schnitzer A, Engel D, et al. Long-term follow-up-findings in mammography and ultrasound after intraoperative radiotherapy (IORT) for breast cancer. Breast. 2009;18(5):327-34.
  27. Sperk E, Welzel G, Keller A, Kraus-Tiefenbacher U, Gerhardt A, Sutterlin M, et al. Late radiation toxicity after intraoperative radiotherapy (IORT) for breast cancer: results from the randomized phase III trial TARGIT A. Breast Cancer Res Treat. 2012;135(1):253-60.
  28. Valentini V, Balducci M, Tortoreto F, Morganti AG, De Giorgi U, Fiorentini G. Intraoperative radiotherapy: current thinking. Eur J Surg Oncol. 2002;28(2):180-5.
  29. Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013;14(13):1269-77.
  30. Michael D, Aron J, Laura J, Catherine C, Brittany L, Rebecca J, et al. Cost-Effectiveness Analysis of Intraoperative Radiation Therapy for Early-Stage Breast Cancer. Ann Surg Oncol. 2013;20:2873-80.
  31. Holmes DR, Pulicharamveettil J, Sutter GL, Rivera RJ, editors. Cost comparison of radiation treatment options after lumpectomy for breast cancer: Intraoperative radiotherapy versus alternatives. ASCO Annual Meeting Proceedings; 2012.
  32. Esposito E, Anninga B, Harris S, Capasso I, D’Aiuto M, Rinaldo M, et al. Intraoperative radiotherapy in early breast cancer. Br J Surg. 2015;102(6):599-610.
  33. Aziz MH, Schneider F, Clausen S, Blank E, Herskind C, Afzal M, et al. Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays? Radiat Oncol. 2011;6:174.
  34. Xie X, Dendukuri N, McGregor M. Single-dose Intraoperative Radiotherapy Using Intrabeam® for Early-stage Breast cancer: A Health Technology Assessment.Montreal (Canada). Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC). 2012;63(28):1-14.
Health Management & Information Science
Volume 3, Issue 2 - Serial Number 2
16
Spring 2016
Pages 33-38